Abstract
HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Current Gene Therapy
Title: Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Volume: 4 Issue: 2
Author(s): Ryuichi Morishita, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Hitomi Kurinami, Shiro Shimizu, Hirofumi Makino, Yasushi Takesya, Junya Azuma and Toshio Ogihara
Affiliation:
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Abstract: HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Export Options
About this article
Cite this article as:
Morishita Ryuichi, Aoki Motokuni, Hashiya Naotaka, Yamasaki Keita, Kurinami Hitomi, Shimizu Shiro, Makino Hirofumi, Takesya Yasushi, Azuma Junya and Ogihara Toshio, Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF), Current Gene Therapy 2004; 4 (2) . https://dx.doi.org/10.2174/1566523043346453
DOI https://dx.doi.org/10.2174/1566523043346453 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease
Current Pharmaceutical Design Non-Peptidic Small-Molecule Antagonists of the Human Platelet Thrombin Receptor PAR-1
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Molecular Imaging of Vascular Thrombosis
Current Molecular Imaging (Discontinued) Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets Acute Decompensated Heart Failure Update
Current Cardiology Reviews Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Managing Cardiovascular Risk Factors without Medications: What is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry